SOT 2019: How to Rationally Adjust Metformin Dose in DDIs Mechanistic Unknowns

BioIVT sponsored an exhibitor-hosted session at 2019 SOT 58TH Annual Meeting and Tox Expo in  which ipadhorizontalleft_909x685 (3)-1Dr. Maciej Zamek-Gliszczynski, GSK, discussed metformin drug-drug interaction (DDI) studies. 

In this session, Dr. Zamek-Gliszczynski presented in vitro and in vivo metformin transporter DDI studies to examine the effects of Famotidine on plasma exposure levels and the glucose-lowering effects. He concluded that because of metformin’s mechanistically complex PK/PD effects, a rational design for metformin clinical DDI studies needed to be performed on new molecular entities that may be co-administered with metformin.

Fill out the form below to download the presentation slides. 

Download Now